Supriya Lifescience Ltd. (SUPRIYA) fundamentals
Supriya Lifescience Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SUPRIYA (ISIN INE07RO01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Supriya Lifescience Ltd. does
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 API products that offer remedies in therapeutic segments, such as antihistamines, analgesics, vitamins, anesthetics and anti-asthmatics, among others. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulfate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others. The Company has manufacturing facilities located in Maharashtra.
Valuation and market data
| Last close | ₹917.45 |
|---|---|
| Market capitalisation | ₹7,385 crore |
| Enterprise value | ₹7,339 crore |
| P/E (TTM) | 0.00 |
| Price to book | 7.41 |
| Price to sales (TTM) | 8.35 |
| Book value per share | ₹123.83 |
| Dividend yield | 10.90% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Dec 28 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹839 crore | ₹275 crore | ₹209 crore | 0.00 |
| Mar 2025 | ₹706 crore | ₹248 crore | ₹188 crore | 23.35 |
| Mar 2024 | ₹581 crore | ₹166 crore | ₹119 crore | 14.80 |
| Mar 2023 | ₹470 crore | ₹123 crore | ₹90 crore | 11.16 |
| Mar 2022 | ₹538 crore | ₹207 crore | ₹152 crore | 18.86 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 68.3% |
|---|---|
| Foreign institutions (FII) | 6.2% |
| Mutual funds | 1.3% |
| Other domestic institutions | 4.0% |
| Retail and others | 20.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.